• Highlighting the key reasons DDR programs stall, including weak mechanistic rationale, limited biomarker support, and poor patient stratification

• Presenting real-world case studies from biotech and academia on programs that failed to translate, and the lessons learned

• Exploring how early decisions around target selection, dosing, and trial design impact clinical success

• Identifying practical strategies to improve target validation, including functional assays, predictive biomarkers, and more robust preclinical models